Erratum to "Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project": [Annals of Oncology 32 (2021) 1626-1636]

Affiliations

• ¹ Friends of Cancer Research, Washington.
• ² National Cancer Institute, Bethesda.
• ³ Molecular Characterization Laboratory, Frederick National Lab for Cancer Research, Leidos Biomedical Research Inc., Frederick.
• ⁴ Foundation Medicine Inc., Cambridge.
• ⁵ NeoGenomics Laboratories, Aliso Viejo, USA.
• ⁶ ACT Genomics, Taipei, Taiwan.
• ⁷ Bristol Myers Squibb Co., Princeton.
• ⁸ AstraZeneca Pharmaceuticals LP, Waltham, USA.
• ⁹ European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
• ¹⁰ LGC Clinical Diagnostics, Gaithersburg.
• ¹¹ OmniSeq Inc., Buffalo.
• ¹² Clinical Sequencing Division, Thermo Fisher Scientific, Ann Arbor.
• ¹³ Intermountain Precision Genomics, St. George.
• ¹⁴ Brigham and Women's Hospital, Boston, USA.
• ¹⁵ QIAGEN Inc, Aarhus, Denmark.
• ¹⁶ Memorial Sloan Kettering Cancer Center, New York.
• ¹⁷ Personal Genome Diagnostics, Baltimore.
• ¹⁸ The University of Texas MD Anderson Cancer Center, Houston.
• ¹⁹ Illumina Inc, Clinical Genomics, San Diego.
• ²⁰ Biodesix, Inc., Boulder.
• ²¹ Johns Hopkins University, Baltimore.
• ²² Caris Life Sciences Inc, Phoenix, Arizona, USA.
• ²³ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
• ²⁴ EMD Serono Research and Development Institute, Inc., Billerica.
• ²⁵ Q Squared Solutions, Durham.
• ²⁶ General Dynamics Information Technology, Inc., Columbia, USA.
• ²⁷ Friends of Cancer Research, Washington. Electronic address: [email protected].